Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium citrate; water for injections; citric acid monohydrate; sodium hydroxide - oxycodone wockhardt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; croscarmellose sodium; magnesium stearate; povidone; hyprolose; silicon dioxide; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - cidala is indicated for the treatment of: - erectile dysfunction (ed) in adult males; - moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; purified water; methyl hydroxybenzoate; citric acid; glycerol; carmellose sodium; sorbitol solution (70 per cent) (crystallising); sucralose; flavour - briviact oral solution is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lercanidipine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; purified talc; microcrystalline cellulose; polyvinyl alcohol; povidone; iron oxide red; macrogol 3350; lactose monohydrate; magnesium stearate; iron oxide yellow; titanium dioxide - treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lercanidipine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; macrogol 3350; microcrystalline cellulose; iron oxide yellow; povidone; purified talc; titanium dioxide; lactose monohydrate; iron oxide red; polyvinyl alcohol - treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lercanidipine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; iron oxide red; iron oxide yellow; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; magnesium stearate; microcrystalline cellulose; povidone - treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - omeprazole, quantity: 20 mg - capsule - excipient ingredients: quinoline yellow; purified water; gelatin; titanium dioxide; sodium lauryl sulfate; dibasic sodium phosphate; mannitol; hypromellose; macrogol 6000; purified talc; polysorbate 80; methacrylic acid copolymer; maize starch; sucrose - the relief of heartburn and other symptoms associated with gord. the treatment and prevention of relapse in erosive oesophagitis. the treatment of duodenal and gastric ulcer. combination therapy for the treatment of peptic ulcer disease associated with h. pylori infection. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs.the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be h. pylori negative, or in whom eradication is inappropriate, e.g. the elderly or ineffective. the treatment of zollinger-ellison syndrome.